Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.72 |
| ▸ | GAA | P10253 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 5/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | MAOB | P27338 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | MMP2 | P08253 | 1/20 | 0.54 |
| ▸ | PPARA | Q07869 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL445511 | 0.91 | L3MBTL1 (0.76) | L3MBTL1GAAMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL13401600 | 0.90 | L3MBTL1 (0.64) | L3MBTL1GAAMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL2213052 | 0.89 | L3MBTL1 (0.79) | L3MBTL1GAAMAPTALDH1A1MAOB | |
| SCHEMBL7568345 | 0.88 | GAA (0.80) | L3MBTL1GAAMAPTALDH1A1MAOB | |
| SCHEMBL13348918 | 0.88 | GAA (0.80) | L3MBTL1GAAMAPTALDH1A1MAOB | |
| SCHEMBL13851444 | 0.87 | L3MBTL1 (0.75) | L3MBTL1GAAMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL834525 | 0.86 | L3MBTL1 (0.88) | L3MBTL1GAAMAPTALDH1A1MAOB | |
| SCHEMBL2234098 | 0.85 | PKM (0.69) | L3MBTL1MAPTALDH1A1MMP2PPARA | |
| SCHEMBL18868405 | 0.84 | L3MBTL1 (1.00) | L3MBTL1GAAMAPTALDH1A1MAOB | |
| SCHEMBL5289695 | 0.83 | L3MBTL1 (0.75) | L3MBTL1GAAMAPTALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| US-9095565-B2 | Methods for treating blood disorders | PHOENICIA BIOSCIENCES, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-9095565-B2 | Methods for treating blood disorders | PHOENICIA BIOSCIENCES, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140301975-A1 | Methods for Treating Blood Disorders | PHOENICIA BIOSCIENCES INC (US) | 2014-10-09 | — | — | US | disclosed |
| US-20140301975-A1 | Methods for Treating Blood Disorders | PHOENICIA BIOSCIENCES INC (US) | 2014-10-09 | — | — | US | disclosed |
| US-8759378-B2 | Methods for treating blood disorders | PHOENICIA BIOSCIENCES, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-8759378-B2 | Methods for treating blood disorders | PHOENICIA BIOSCIENCES, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| WO-2011127933-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2011-10-20 | — | — | WO | disclosed |
| EP-1389616-B1 | 3,4-Dihalobenzylpiperidine derivatives and their medical use | MITSUBISHI TANABE PHARMA CORP (JP) | 2011-07-27 | — | — | EP | disclosed |
| US-20090137567-A1 | Methods for Treating Blood Disorders | HEMAQUEST PHARMACEUTICALS, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20090137567-A1 | Methods for Treating Blood Disorders | HEMAQUEST PHARMACEUTICALS, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20080075692-A1 | prophylaxis of blood disorder such as sickle cell anemia, beta -thalassemia, neutropenia or thrombocytopenia, comprising administering carboxylic acids, that stimulates production of fetal hemoglobin, hematopoiesis, erythropoiesis, myelopoiesis and neutrophil production | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION | 2008-03-27 | — | — | US | disclosed |
| US-20080075692-A1 | prophylaxis of blood disorder such as sickle cell anemia, beta -thalassemia, neutropenia or thrombocytopenia, comprising administering carboxylic acids, that stimulates production of fetal hemoglobin, hematopoiesis, erythropoiesis, myelopoiesis and neutrophil production | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION | 2008-03-27 | — | — | US | disclosed |
| WO-2007133653-A2 | METHODS FOR TREATING BLOOD DISORDERS | HEMAQUEST PHARMACEUTICALS, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| US-7115635-B2 | Benzylpiperidine compound | MITSUBISHI PHARMA CORPORATION (JP) | 2006-10-03 | — | — | US | disclosed |
| US-20040158071-A1 | Chemokine inhibitors and stability in blood | MITSUBISHI PHARMA CORPORATION (JP) | 2004-08-12 | — | — | US | disclosed |
| EP-1389616-A1 | NOVEL BENZYLPIPERIDINE COMPOUND | Mitsubishi Pharma Corporation (JP) | 2004-02-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140301975-A1 | Methods for Treating Blood Disorders | HBB, HBG1, HBG2 | L3MBTL1 708/4885GAA 181/4885MAPT 2978/4885 |
| US-20090137567-A1 | Methods for Treating Blood Disorders | HBB, HBG1, HBG2 | L3MBTL1 708/4885GAA 181/4885MAPT 2978/4885 |
| US-20040158071-A1 | Chemokine inhibitors and stability in blood | CCL2, CXCR1, CCR5 | L3MBTL1 3984/4885GAA 3114/4885MAPT 4797/4885 |
| US-20080075692-A1 | prophylaxis of blood disorder such as sickle cell anemia, beta -thalassemia, neutropenia or thrombocytopenia, comprising administering carboxylic acids, that stimulates production of fetal hemoglobin, hematopoiesis, erythropoiesis, myelopoiesis and neutrophil production | HBG1, HBG2, HBB | L3MBTL1 2416/4885GAA 107/4885MAPT 3608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.